JP4546790B2 - Lower fatty acid production inhibitor that does not sterilize skin resident bacteria - Google Patents

Description

The present invention relates to a lower fatty acid that does not sterilize skin resident bacteria consisting of a plant extract that suppresses the production of lower fatty acids, which are prominent components of human unpleasant body odor, by skin resident bacteria and a solvent that dissolves the plant extract. It relates production inhibitor, and more particularly, relates to a lower fatty acid production inhibitor that does not sterilize the skin indigenous bacteria have a generation suppressing effect of lower fatty acids by the skin flora sustained without disinfecting the skin indigenous bacteria is there.

  Conventionally, deodorization technology and masking technology have been the mainstream methods for preventing body odor such as sweat odor. In recent years, a method for suppressing the generation of body odor has been put into practical use by a sterilization technique for sterilizing causative bacteria that produce a body odor causing substance. However, deodorization technology and masking technology are not satisfactory in terms of the degree of effect and sustainability, and sterilization technology also sterilizes skin resident bacteria other than odor-producing bacteria, so there is a concern of reducing the skin barrier function (For example, refer nonpatent literature 1).

  Therefore, recently, a technique for suppressing the generation of body odor without sterilizing the skin resident bacteria has been proposed. In metabolism of skin resident bacteria, for example, substances causing body odor such as lower fatty acids are produced. The technique suppresses the generation of a body odor causing substance by inhibiting the metabolic enzymes of skin resident bacteria, thereby suppressing the generation of body odor.

  For example, (Z) -3,4,5,6,6-pentamethylhept-3-ene- can be used as an inactivating agent for microorganisms that generate a malodor of the body containing corynebacteria that are a kind of skin resident bacteria. Fragrance components such as 2-one, diethyl-cyclohex-2-en-1-one and dimethyl-cyclohex-2-en-1-one, citronellol, etc. have been studied, and the lower fatty acid content can be reduced without sterilizing odor-producing bacteria. It has been reported that generation can be suppressed (see Patent Document 1).

  In addition, as β-glucuronidase inhibitors that suppress the production of androste 16-enes, which are said to be the causative odor of human body odor, mainly due to skin resident bacteria, for example, Ogon, Gobishi, Gardenia, Shikon, Peonies, Plant extracts such as enamels, chamomiles, and cypresses have been studied, and it has been reported that the generation of unpleasant body odors can be suppressed without sterilizing skin resident bacteria (see Patent Document 2).

  In addition, as an ester degradation inhibitor that suppresses the production of lower fatty acids, which are said to be the cause odor of human body odor, by skin resident bacteria, aroma components such as benzaldehyde, benzyl benzoate, cinnamic aldehyde, and ethyl vanillin have been studied, and the skin It has been reported that unpleasant body odor can be suppressed without sterilizing resident bacteria (see Patent Document 3).

  Furthermore, inhibition of leucine dehydrogenase contained in the production pathway of isovaleric acid, which is one of the lower fatty acids that cause body odor and is considered to be the main odor substance of sweat odor (see Non-Patent Document 2) As the agent, plant extracts such as Mizuki, Hakunetsugi, Shishiakuchi, Adek, Kanrenboku, and Ezomisohagi and eugenol have been studied, and the deodorizing effect and high safety of these leucine dehydrogenase inhibitors have been reported (Patent Document 4). reference).

  As described above, highly safe aroma components and fragrance components that suppress the generation of body odor without sterilizing skin resident bacteria, and highly safe plants exhibiting a deodorizing action by inhibiting the production pathway of lower fatty acids Extracts are being considered. As a result of examining reports on the pharmacological action of other plants, antibacterial effect (see Patent Documents 5 and 6) for honeysuckle, anti-itch effect (see Patent Document 7), and antibacterial effect for Hypericum perforatum (Patent Documents 6 and 8) Reference), itch prevention effect (see patent document 7), sedgena itch prevention effect (see patent document 7), deodorization effect (see patent document 9), oyster leaf with deodorization effect (see patent documents 10 and 11) , Bactericidal effect (see Patent Document 12), rosemary has a deodorizing effect (see Patent Documents 8, 13, and 14), bactericidal effect (see Patent Documents 10 and 6), and masking effect (see Patent Documents 15 and 16). Although it has been reported respectively, it has not been reported whether it has an effect of suppressing the production of the lower fatty acids.

Katsuyuki Takeda, “The New Knowledge of Skin Defense Function: Role of Acnes and Epidermidis as Permanent Bacteria”, Journal of the Japan Cosmetic Science Society, 2003, Vol. 27, No. 1, p. 29-32 Sawano Kiyohito, "What is body odor-Volatile substances emanating from humans", Perfume, June 1994, No. 182, p. 123-130 JP-T-2002-519368 JP 2002-255776 A JP 09-194340 A JP 2002-87973 A JP 2000-191511 A JP 2003-1113013 A JP 2003-55241 A JP 2004-049889 A JP-A-10-158137 Japanese Patent Laid-Open No. 01-68264 JP 2001-302483 A Japanese Patent Laid-Open No. 11-171720 JP 2003-024422 A JP 2003-113392 A JP-A-11-286428 JP-T-2002-519367

  However, the microorganism inactivation agent that generates the malodor of the body containing the corynebacteria uses a fragrance component as the inactivation agent, and since the component has high volatility and low retention, the body odor is suppressed. The effect which can be satisfied in the point of sustainability is not acquired (refer patent document 1).

  In addition, since the causative substance of body odor that can be suppressed by the β-glucuronidase inhibitor is mainly glandular odor and the effect of suppressing the production of androste 16-enes is insufficient, the β-glucuronidase Satisfactory effects have not been obtained with inhibitors (see Patent Document 2).

  Moreover, since the said ester decomposition inhibitor is inadequate in the production | generation suppression of the lower fatty acid which is a main odor substance of body odor, the effect which is satisfactory in the point of suppression of body odor is not acquired (refer patent document 3). Furthermore, since the inhibitor of leucine dehydrogenase is insufficient in suppressing the formation of isovaleric acid, a satisfactory effect in terms of suppressing body odor has not been obtained (see Patent Document 4). This is because multiple pathways are considered to be involved in the production of lower fatty acids such as isovaleric acid, so that ester degradation inhibitors and leucine dehydrogenase inhibitors only block some of these pathways. It seems to be due to such.

This invention is made | formed in view of the above, Comprising: The objective of this invention can suppress continuously the production | generation of the lower fatty acid which is one of the causative substances of body odor, without killing skin resident bacteria. An object of the present invention is to provide a lower fatty acid production inhibitor that does not sterilize skin resident bacteria comprising a specific plant extract and a solvent that dissolves the plant extract .

  In order to solve the above-mentioned problems, the present inventors have made extensive studies on the action of suppressing the production of the lower fatty acids with respect to various plant extracts. Without killing, regardless of the presence or absence of known metabolic pathway inhibition in skin resident bacteria, we found the effect of highly and continuously suppressing the production of lower fatty acids, one of the main body odor causative substances, The invention has been completed.

That is, the lower fatty acid production inhibitor that does not sterilize skin resident bacteria of the present invention comprises a specific plant extract having an inhibitory effect on the lower fatty acid production of skin resident bacteria and a solvent that dissolves the plant extract. It is characterized by. It is necessary that the specific plant extract does not exhibit bactericidal action against skin resident bacteria. The lower fatty acids are isovaleric acid and caproic acid.

  It is preferable that the isovaleric acid production suppression rate of the plant extract is 90% to 100% in a lower fatty acid production system using Corynebacterium xerosis, which is a kind of skin resident bacteria. The suppression rate of caproic acid production of the plant extract is preferably 75% to 100% in the lower fatty acid production system using Propionibacterium acnes.

When the lower fatty acid is isovaleric acid, the plant as a source of the specific plant extract is at least one selected from honeysuckle and hypericum perforatum, and when the lower fatty acid is caproic acid, oyster leaves , At least one selected from Hypericum perforatum, Hawthorn, Bodaige and Rosemary.

In addition, the lower fatty acid production inhibitor that does not sterilize skin resident bacteria of the present invention can be used as an additive component for the purpose of suppressing body odor generation, for example, in preparations such as cosmetics, pharmaceuticals, and quasi drugs.

The lower fatty acid production inhibitor that does not sterilize skin resident bacteria of the present invention is a specific plant that can continuously suppress the production of lower fatty acids, which is one of the main causative substances of body odor, without killing the skin resident bacteria. It is characterized by comprising an extract and a solvent that dissolves the plant extract, and by using the lower fatty acid production inhibitor that does not sterilize the skin resident bacteria of the present invention as an additional component , a highly safe body odor It is possible to provide a preparation selected from cosmetics, pharmaceuticals, and quasi-drugs having an inhibitory effect on generation.

Hereinafter, embodiments of the present invention will be described.
The lower fatty acid production inhibitor that does not sterilize skin resident bacteria of the present invention comprises a specific plant extract having an inhibitory effect on the lower fatty acid production of skin resident bacteria and a solvent that dissolves the plant extract. And The lower fatty acids are the main causative substances of body odor and are known to be produced by metabolism of skin resident bacteria. Therefore, the lower fatty acid production inhibitor that does not sterilize skin resident bacteria of the present invention, which comprises a plant extract capable of suppressing the production of lower fatty acids due to metabolism of skin resident bacteria and a solvent that dissolves the plant extract, is unpleasant. It can be suitably used for a preparation that at least has an action of effectively suppressing body odor.

As metabolic pathways related to the production of lower fatty acids in skin resident bacteria, metabolic pathways of ester degradation and leucine dehydrogenation are known, but other metabolic pathways are unknown. In order to effectively suppress unpleasant body odor, it can be used as an additive component in various preparations such as cosmetics, pharmaceuticals, and quasi drugs regardless of the presence or absence of such an inhibitory action on metabolic pathways. , it is important to provide a lower fatty acid production inhibitor that does not sterilize the skin indigenous bacteria have a generation suppressing effect of lower fatty acid which is the main causative agent of body odor.

Moreover, it is necessary that the plant extract contained in the lower fatty acid production inhibitor of the present invention does not exhibit bactericidal action against skin resident bacteria. By appropriately adjusting the blending ratio of the plant extract, the lower fatty acid production inhibitor that does not sterilize skin resident bacteria of the present invention produces a lower fatty acid without sterilizing the skin resident bacteria. High suppression effect itself. As the compounding amount of each plant extract in each preparation after adding the lower fatty acid production inhibitor of the present invention to each preparation, it is generally better to add 0.1% by mass or less in terms of solids, Preferably it is 0.05% by mass or less.

A typical example of the lower fatty acid is isovaleric acid, which is known as a main odor substance of sweat odor and foot odor. Lower fatty acids other than isovaleric acid are also involved as causative substances of body odor, and examples thereof include caproic acid, butyric acid, and caprylic acid. On the other hand, the lower fatty acid production inhibitor that does not sterilize skin resident bacteria of the present invention comprises a specific plant extract that suppresses the production of isovaleric acid and / or caproic acid as a lower fatty acid by a specific skin resident bacteria. contains.

As a metabolic pathway related to the production of isovaleric acid, a metabolic pathway from leucine is known, but other metabolic pathways are unknown. As one of the metabolic pathways related to the production of other lower fatty acids such as caproic acid, butyric acid and caprylic acid, a pathway from glycerides is known, but the other metabolic pathways are unknown. Therefore, regardless of the presence or absence of an inhibitory action on these known metabolic pathways, lower fatty acids that do not sterilize skin resident bacteria having the effect of suppressing the production of isovaleric acid and / or caproic acid, which are the main causative substances of body odor. It is important to provide a production inhibitor.

Different skin resident bacteria are strongly involved in the production of isovaleric acid and caproic acid. In the production of isovaleric acid, the involvement of Corynebacterium xerosis is particularly strong among the skin resident bacteria, and in the production of caproic acid, the involvement of Propionibacterium acnes is particularly strong among the skin resident bacteria. It is said. On the other hand , as a lower fatty acid production inhibitor that does not sterilize skin resident bacteria of the present invention, the specific plant extract that suppresses the production of isovaleric acid by Corynebacterium xerosis which is the skin resident bacteria , and the above It contains at least a specific plant extract that suppresses the production of caproic acid by Propionibacterium acnes, which is a skin resident bacteria .

The rate of inhibition of isovaleric acid production of the specific plant extract contained in the lower fatty acid production inhibitor that does not sterilize skin resident bacteria of the present invention is Corynebacterium xerosis, a kind of skin resident bacteria. It is preferably 90% to 100% in the isovaleric acid production system using

  The isovaleric acid production system using Corynebacterium xerosis is, as shown in Examples 1 to 3 described later, 5 ml of sweat collected from a healthy boy and immediately filter sterilized, and then corynebacterium. This refers to an isovaleric acid production system in which about 8 LOG CFU / ml of xylosis (Corynebacterium xerosis) is inoculated and reacted at 37 ° C. for 6 hours. The plant extract exhibits a high isovaleric acid production inhibitory effect of 90% to 100% in this system.

The production inhibition rate of caproic acid in the specific plant extract contained in the lower fatty acid production inhibitor that does not sterilize skin resident bacteria of the present invention is the Propionibacterium acnes which is a kind of skin resident bacteria. ) Is preferably 75% to 100% in the lower fatty acid production system.

The lower fatty acid production system using Propionibacterium acnes is 1 × 10 ⁸ Propionibacterium acnes in Tricaproin as shown in Examples 4 to 8 described later. / ML refers to a lower fatty acid production system in which the reaction is performed at 37 ° C. for 6 hours. The plant extract exhibits a high lower fatty acid production inhibitory effect of 75% to 100% in this system.

Although it is not clear what metabolic pathway the specific plant extract contained in the lower fatty acid production inhibitor that does not sterilize skin resident bacteria of the present invention blocks or by which action mechanism, it is the main body odor It has a high production inhibitory effect of isovaleric acid itself or caproic acid itself as causative substances.

  The plant serving as a source of a plant extract effective for suppressing the production of isovaleric acid by the resident skin bacterium is preferably at least one plant selected from honeysuckle, Hypericum perforatum, and horsetail. Such a plant is not particularly limited in its part, but from the viewpoint of exerting its effectiveness, honeysuckle (Lonicera japonica) is flower bud (gold and silver flower), Hypericum perforatum is above-ground part, cedar (Equisetum arvense) It is preferable to use the above-ground part.

The plant serving as the source of the specific plant extract effective for suppressing the production of caproic acid by the skin resident bacteria is at least one plant selected from oyster leaves, Hypericum perforatum, Hawthorn, Bodaige, and Rosemary. Preferably there is. The plant used for the extraction of such a plant extract is not particularly limited in its application part, but from the viewpoint of exerting its effectiveness, oysters are leaves, hypericum persimmons are above-ground parts, hawthorn is flowers, leaves or fruits, It is preferable to use flowers or leaves for the body, and leaves or flowers and leaves for the rosemary.

  As the plant extract, an extract obtained by extracting the pulverized product obtained by cutting or grinding it to an appropriate size after the part is raw or dried, or further separated and purified components can be used. . The extract can be obtained by solvent extraction by a conventional method. If the extraction solvent is harmless in use, the extract may be used as it is, may be used as a diluted solution diluted with an appropriate solvent, or it may be a concentrated extract, or a dry powder by freeze drying, or a paste What was prepared in the shape of a thing etc. can be utilized as said plant extract.

  Examples of the extraction solvent include generally used organic solvents such as methanol, ethanol, butanol, hexane, heptane, cyclohexane, ethyl acetate, acetone, monoterpenes, glycerin, 1,3-butylene glycol, dipropylene glycol, propylene glycol, and the like. These glycols and water can be used, and one of these can be used alone, or two or more can be used in combination. Among these solvents, ethanol, water, 1,3-butylene glycol, monoterpenes, and mixed solvents thereof are particularly desirable from the viewpoint of extraction efficiency.

  In addition, the said extraction process can be performed by conventional methods, such as a cold immersion, digestion, a heating recirculation | reflux, and a percolation method. In addition to solvent extraction, extracts obtained by supercritical extraction performed by steam distillation or carbon dioxide gas in a supercritical state can also be used. In supercritical extraction, hexane, ethanol or the like can be used as an extraction aid.

The extract can be separated and purified by activated carbon treatment, liquid-liquid distribution, column chromatography, liquid chromatography, or the like.
Other extraction conditions are not particularly limited, such as extraction temperature and extraction pH.

A specific plant having at least one plant selected from honeysuckle, hypericum perforatum, oyster leaf, hawthorn, bodice, and rosemary, contained in the lower fatty acid production inhibitor that does not sterilize skin resident bacteria of the present invention. By adjusting the blending amount with a solvent , the extract can suppress the generation of lower fatty acids without killing the skin resident bacteria.

  Although the specific compounding quantity of the said plant extract is suitably selected according to the use of a composition, a dosage form, etc., generally 0.0001-0.1 mass% (henceforth only "" % ”)), Preferably 0.0001 to 0.05%. If the blending amount is less than 0.0001% by mass, the effect of the present invention cannot be exhibited, and if it is 0.1% by mass or more, an action to sterilize skin resident bacteria occurs. The bactericidal action here refers to SCD medium containing 0.1% Tween 80, the test substance added, and ingesting skin resident bacteria (Corynebacterium xerosis), after reaction at 37 ° C. for 6 hours, On the other hand, the effect of reducing to 1/100 or less, or the modified GAM agar medium to which test substance was added, ingested skin resident bacteria (Propionibacterium acnes), and after reaction in anaerobic condition at 37 ° C. for 6 hours, control In contrast, this means an action that decreases to 1/100 or less.

If the lower fatty acid production inhibitor that does not sterilize the skin resident bacteria of the present invention is used as an additive component in various preparations, various preparations that at least exert the action of effectively suppressing unpleasant body odor can be obtained.

  Examples of the preparation include cosmetics, pharmaceuticals, quasi drugs, and the like, and can be prepared as creams, emulsions, lotions, powders, sprays, sticks, body soaps, shampoos, rinses, tonics, and the like. .

In this case, manufacturing agent added a lower fatty acid production inhibitor of the present invention, the type of each formulation, a known compounding ingredients depending on the dosage form by a conventional method can be prepared with. For example, surfactants, oils, alcohols, moisturizers, thickeners, preservatives, chelating agents, pH adjusters, fragrances, pigments, UV absorbers / scatterers, vitamins, water, etc. can do. In addition, the preparation obtained by adding the lower fatty acid production inhibitor of the present invention can be blended with commonly used deodorants, preservatives, antioxidants and the like in addition to the above active ingredients. .

Hereinafter, the present invention will be described in more detail based on examples. In addition, this invention is not limited to the following Example.
Lower fatty acid is a major component of body odor, and various lower fatty acids cause body odor. Among them, isovaleric acid is particularly problematic as sweat odor and foot odor, and is particularly problematic as odor. Is caproic acid. In the simulated production system of caproic acid in this example, tricaproin, which is a triglyceride of caproic acid, was used as the precursor of caproic acid. However, the precursor of caproic acid used in the simulated production system was triglyceride of caproic acid. It is not limited.

<Preparation Example 1> Preparation of Specific Plant Extract and Lower Fatty Acid Production Inhibitor for Isovaleric Acid Production Inhibition Test Honeysuckle is a flower bud and Hypericum perforatum is dried and pulverized to obtain crude powder. The sample was immersed in 100 mL of 100% ethanol and extracted at room temperature for 5 days. The extract obtained by filtering the residue was concentrated under reduced pressure to obtain a lower fatty acid production inhibitor comprising each plant extract and a solvent for dissolving the plant extract .

<Preparation Example 2> Preparation of Specific Plant Extract and Lower Fatty Acid Production Inhibitor for Caproic Acid Production Inhibition Test Oysters are leaves, Hypericum perforatum is above ground, Hawthorn is flowers, leaves or fruits, Bodaiju is flowers or leaves In the case of roastmary, leaves or flowers and leaves were dried and pulverized to obtain a coarse powder, 10 g of each was taken, immersed in 100 mL of 100% ethanol, and extracted at room temperature for 5 days. The extract obtained by filtering the residue is concentrated to dryness, and dissolved in 100 mL of 100% ethanol in an arbitrary amount to obtain a lower fatty acid production inhibitor comprising each plant extract and a solvent for dissolving the plant extract. It was.

<Examples 1 and 2> Isovaleric acid production inhibition test To 5 mL of sweat collected from healthy boys and immediately filter sterilized, each lower fatty acid production inhibitor obtained according to Preparation Example 1 was 250 μg / mL, Corynebacterium xerosis (Foundation) Incorporation of about 8 Log CFU / mL was allowed to react at 37 ° C. for 6 hours. After measuring the number of viable bacteria, 0.5 mL of 10% sulfuric acid and 3 mL of diethyl ether were added to 2 mL of the reaction solution from which the bacteria were removed by filtration, and the amount of isovaleric acid extracted in the ether layer was measured by gas chromatography. . Table 1 shows the results of calculating the production inhibition rate (%) of isovaleric acid and the number of viable bacteria with respect to a control not containing each test substance (Comparative Example 3 below).

  In addition, as a comparative example, Dioh (Rehmannia glutinosa) extract, benzalkonium chloride (manufactured by Kanto Chemical Co., Ltd.), and a control not containing each test substance (Comparative Example 3) were similarly tested, and the results are shown in Table 1. (Comparative Examples 1 and 2).

As shown in Table 1 above, the lower fatty acid production inhibitor comprising each extract of honeysuckle and Hypericum perforatum and a diluent solvent suppresses the generation of isovaleric acid without sterilizing the skin resident bacteria. The effect was recognized.

<Examples 3 to 7> Caproic acid production inhibition test Each lower fatty acid production inhibition obtained according to Preparation Example 2 in 2.5 mL of 0.2% tricaproin-0.05M phosphate buffer pH 6.0 (manufactured by SIGMA) The agent was inoculated with 250 μg / mL and Propionibacterium acnes (ATCC) of about 1 × 10 ⁸ cells / mL, and reacted at 37 ° C. for 6 hours in an anaerobic state. After measuring the number of viable bacteria, 0.5 mL of 10% sulfuric acid and 3 mL of diethyl ether were added to the reaction solution, and the amount of caproic acid extracted in the ether layer was measured by gas chromatography. Table 2 shows the results of calculating the production inhibition rate (%) of caproic acid and the number of viable bacteria with respect to a control not containing each test substance (Comparative Example 6 below).

  Moreover, as a comparative example, a gentian extract, benzalkonium chloride (manufactured by Nacalai Tex Co., Ltd.), and a control not containing each test substance (Comparative Example 6) were similarly tested, and the results are shown in Table 3 (Comparison) Examples 4 and 5).

As in the results shown in Table 2 above, the lower fatty acid production inhibitor consisting of oyster leaves, Hypericum perforatum, Hawthorn, Bodaige, Rosemary extract and a diluent solvent should be used to sterilize skin resident bacteria. The effect of suppressing the generation of caproic acid was observed.

<Formulation Examples 1 to 21>
In Tables 4 to 10 below, body soap, powder spray type antiperspirant, roll-on type antiperspirant, deodorant formulated with lower fatty acid production inhibitors consisting of extracts of honeysuckle, hypericum perforatum, and horsetail, and a diluent solvent Formulation examples 1 to 21 of sticks, shampoos, rinses, and hair waters are shown. In addition, each plant extract (lower fatty acid production inhibitor) described below was extracted by the extraction method shown in <Preparation Example 1>. In addition, the fragrance | flavor described in the composition adds 0.001% of dibutylhydroxytoluene to the fragrance | flavor described in Unexamined-Japanese-Patent No. 2003-300811.

Each formulation of the following formulation examples 1-21 was excellent in the production | generation suppression effect of isovaleric acid, and the safety | security was also favorable.

<Formulation examples 22-56>
Below, body soap, powder spray type antiperspirant, roll-on type antiperspirant, containing lower fatty acid production inhibitor consisting of each extract of oyster leaves, Hypericum perforatum, Hawthorn, Bodaige, Rosemary and diluent solvent , Deodorant stick, shampoo, rinse, and hair water formulation examples 22-56 are shown. In addition, each plant extract (lower fatty acid production inhibitor) described below was extracted by the extraction method shown in <Preparation Example 2>. In addition, the fragrance | flavor described in the composition adds 0.001% of dibutylhydroxytoluene to the fragrance | flavor described in Unexamined-Japanese-Patent No. 2003-300811.

  Each formulation of the following formulation examples 22-56 was excellent in the production | generation suppression effect of a caproic acid, and the safety | security was also favorable.

Powder spray type antiperspirant

Roll-on type antiperspirant

Deodorant stick

Body soap

shampoo

rinse

Hair water

As described above, the lower fatty acid production inhibitor that does not sterilize skin resident bacteria according to the present invention comprises a plant extract that suppresses the generation of lower fatty acids, which is a major component of human unpleasant body odor, and a diluent solvent, As its application, it is suitable for use as an additive component of highly safe cosmetics , pharmaceuticals, and quasi-drugs that continuously suppress unpleasant body odors of humans without sterilizing skin resident bacteria.

Claims (4)

A lower fatty acid production inhibitor that does not sterilize skin resident bacteria without sterilizing skin resident bacteria without sterilizing skin resident bacteria on the body surface,
An extract of at least one plant selected from honeysuckle and hypericum perforatum having an action of suppressing the production of isovaleric acid, which is a kind of the lower fatty acid, by Corynebacterium xerosis, which is a resident skin bacterium, and Corynebacterium xerosis It comprises a solvent that dissolves the plant extract, and contains 0.0001 to 0.1% by mass of the plant extract on the basis of solid content. Agent. A lower fatty acid production inhibitor that does not sterilize skin resident bacteria without sterilizing skin resident bacteria without sterilizing skin resident bacteria on the body surface,
It is selected from oyster leaves, Hypericum perforatum, Hawthorn, Bodaige, Rosemary, which have an action of suppressing the production of caproic acid, which is one of the lower fatty acids, by Propionibacterium acnes, which is the resident skin bacterium. It is composed of at least one plant extract and a solvent that dissolves the plant extract, and contains 0.0001 to 0.1% by mass of the plant extract based on the solid content. Lower fatty acid production inhibitor that does not sterilize bacteria. A lower fatty acid production inhibitor that does not sterilize skin resident bacteria without sterilizing skin resident bacteria without sterilizing skin resident bacteria on the body surface,
It is a mixture of the lower fatty acid production inhibitor that does not sterilize skin resident bacteria according to claim 1 and the lower fatty acid production inhibitor that does not sterilize skin resident bacteria according to claim 2. Lower fatty acid production inhibitor that does not sterilize skin resident bacteria. 4. The lower fatty acid production inhibitor according to claim 3, wherein the plant extract in the mixture is an extract of Hypericum perforatum.